Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,720.22
(
0.31%
)
US TECH 100
24,161.20
(
0.61%
)
Dow Jones
47,035.00
(
0.19%
)
Brent Oil
100.90
(
2.64%
)
Bitcoin
74,623.80
(
-0.29%
)
News Focus
News Focus
Post# of 257252
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122792
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 91163

Thursday, 02/25/2010 2:07:55 PM

Thursday, February 25, 2010 2:07:55 PM

Post# of 257252
I draw a distinction between: a) ritonavir boosting to convert a BID/TID drug into a qD drug; and b) ritonavir boosting to try to salvage a drug that has a small (or nonexistent) therapeutic window.

What ITMN is doing with ITMN-191 falls within case b, and that’s why I’m skeptical of the outcome.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now